ProfileGDS5678 / 1440704_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 57% 55% 55% 54% 55% 61% 54% 54% 60% 55% 55% 54% 54% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.479157
GSM967853U87-EV human glioblastoma xenograft - Control 23.3591555
GSM967854U87-EV human glioblastoma xenograft - Control 33.3620155
GSM967855U87-EV human glioblastoma xenograft - Control 43.265554
GSM967856U87-EV human glioblastoma xenograft - Control 53.3288755
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7144961
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4141254
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3459954
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5830160
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3580855
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3682655
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2980654
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3655854
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3609755